Royalty Pharma Announces Significant Dividend Payment Details

Author: Owen Jenkins Updated: 07-18-2025 08:29 AM

Royalty Pharma's Recent Dividend Announcement

The board of directors of Royalty Pharma plc (NASDAQ: RPRX) has decided to declare a dividend for the third quarter of the year 2025. This dividend is set at $0.22 per Class A ordinary share, which reflects the company’s consistent commitment to rewarding its shareholders.

Dividend Payment Dates

This dividend is scheduled to be paid on September 10, 2025, to shareholders who are on record by the close of business on August 15, 2025. This timeline ensures that eligible investors can benefit from the dividend payout during this period.

About Royalty Pharma

Established in 1996, Royalty Pharma has emerged as the largest purchaser of biopharmaceutical royalties worldwide. The company is committed to fostering innovation throughout the biopharmaceutical field. By collaborating with a broad range of innovators, including universities, research hospitals, and biotechnology firms, Royalty Pharma has built an impressive portfolio of royalty rights on many leading therapies.

Portfolio Highlights

Royalty Pharma's portfolio currently includes royalties from over 35 commercial products. This includes notable drugs like Vertex's Trikafta, which has significantly transformed care for cystic fibrosis patients, and GSK's Trelegy, a triple-combination inhaler for chronic obstructive pulmonary disease (COPD). Additionally, the portfolio features Roche's Evrysdi, Johnson & Johnson's Tremfya, and Biogen's Tysabri and Spinraza, among others.

Funding Innovation

Royalty Pharma is not only involved in acquiring existing royalties but also actively participates in creating new opportunities. The company partners with biopharmaceutical developers to co-fund late-stage clinical trials and new product launches, with the expectation of receiving future royalties. This business model allows them to support innovative treatments while also ensuring rewarding returns for their investors.

Investor Relations Contact Information

Royalty Pharma encourages interested parties to reach out for investor relations inquiries. The contact number for investor relations is +1 (212) 883-6637. Investors can also contact the company via email at ir@royaltypharma.com.

Frequently Asked Questions

What is the dividend amount declared by Royalty Pharma?

Royalty Pharma has declared a dividend of $0.22 per Class A ordinary share for the third quarter of 2025.

When will the dividend be paid?

The dividend is set to be paid on September 10, 2025, to eligible shareholders.

When is the record date for the dividend?

The record date for this dividend payment is August 15, 2025.

What is the primary focus of Royalty Pharma?

Royalty Pharma is focused on purchasing biopharmaceutical royalties and funding innovations within the biopharmaceutical industry.

How can investors contact Royalty Pharma for inquiries?

Investors can contact Royalty Pharma at +1 (212) 883-6637 or via email at ir@royaltypharma.com.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.